Skip to content

Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long COVID
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
      • TNX-3600
      • TNX-3800
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling participants in a Phase 3 trial for Fibromyalgia (RESILIENT study) and a Phase 2 trial for Long COVID (PREVAIL study). Please visit Clinical Trials.

September 2022

Long-term Rejection Free Renal Allograft Survival with Fc-modified Anti-CD154 Antibody Monotherapy in Nonhuman Primates

Sign up for Email Alerts
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.

Cookie Notification
We use 1st and 3rd party cookies to enhance your experience of our website, save your preferences, and provide us with information on how you use our website. For more information, please refer to our Privacy Policy. By accessing or using our website, you consent to our use of cookies. You may opt out of the use of cookies by adjusting your browser settings.

Accept